Introduction {#Sec1}
============

The efficacy of celecoxib for the treatment of osteoarthritis (OA) has been well established, both in largely Caucasian populations \[[@CR1]--[@CR3]\] and in patients of various other ethnicities, including Asian patients \[[@CR4]--[@CR6]\]. The efficacy of other nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of OA has also been well established in a number of trials conducted in Asian countries \[[@CR7], [@CR8]\].

There are commonly differences in body mass and body shape between Asian patients and patients of other ethnicities, with Asian patients often being smaller and having a lower body mass index \[[@CR9]\]. As a result, there is a perception that Asian patients may require lower doses of medications, including treatments for pain \[[@CR8]\], and there is an unsupported assumption by some healthcare professionals that celecoxib treatment may be less efficacious, or should be utilized at lower doses, in Asian patients with OA.

This report is a comparison of the results from two randomized clinical trials of celecoxib for the treatment of OA: one in Asian patients and one in non-Asian patients. Direct comparison of the efficacy and safety of celecoxib in these two populations aims to assess the possibility of any significant difference in response to, or tolerance of, OA treatment in Asian patients.

Methods {#Sec2}
=======

Study Populations {#Sec3}
-----------------

This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. Study A3191052 ("Asian" study) was a 6-week, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of once-daily celecoxib versus twice-daily naproxen in Asian patients with OA of the knee in the United States \[[@CR5]\]. Patients were randomized 2:2:1 to celecoxib 200 mg once daily, naproxen 500 mg twice daily, or placebo. The study is registered on ClinicalTrials.gov (NCT00620867).

To select the most appropriate comparator trial, all Pfizer-sponsored studies of celecoxib for the treatment of OA were reviewed based on the following criteria: only randomized, controlled trials of celecoxib of comparable duration; conducted in a mixed population in which the majority of patients were non-Asian; included an active comparator that is currently available to patients; and included efficacy endpoints that were comparable to study A3191052. Ten Pfizer-sponsored studies of celecoxib for the treatment of OA were identified, of which only one study met all of the above criteria. Study A3191063 ("non-Asian" study) was a 6-week, multicenter, randomized, double-blind, placebo-controlled, active-comparator, parallel-group study in patients with OA of the knee. Patients were randomized 2:2:1 to celecoxib 200 mg once daily, ibuprofen 800 mg three times daily, or placebo. The study was conducted in 32 centers in the United States in a mixed population of which 89.6% were non-Asian. Asian patients were excluded for this analysis. Study A3191052 is not registered on ClinicalTrials.gov.

Both trials were conducted between 2002 and 2003. Patients were included in either study if they were diagnosed with OA of the knee according to the American College of Rheumatology (ACR) guidelines \[[@CR10]\], had a functional capacity class of I--III, were eligible, in the investigator's opinion, for daily therapy with an NSAID, and had completed a washout period of ≥2 days prior to baseline assessments. Patients taking ≤325 mg acetylsalicylic acid daily for cardiovascular prophylaxis and who had been on a stable dose for 30 days were also included.

In the Asian study, patients were aged ≥45 years and of self-reported Asian descent. In the non-Asian study, patients were aged ≥40 years. Patients were excluded from either study if they had: inflammatory arthritis, acute joint trauma, active GI disease, been diagnosed with unstable cardiovascular disease within the past 6 months, or had taken acetaminophen within 24 h of the baseline visit (acetaminophen was permitted as rescue medication).

In both studies, the primary efficacy outcome was the change from baseline to week 6 in the Patient's Assessment of Arthritis Pain, as measured on a visual analog scale (VAS; measured from 0--100 mm). As a secondary outcome, both trials assessed the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index, a self-administered questionnaire consisting of 24 items: five regarding pain, two regarding stiffness, and 17 regarding physical function. Responses to each question ranged from "0" (none) to "4" (extreme). The total score (ranging from 0 to 96) is reported with a negative change from baseline, indicating improvement. Safety was assessed by measuring adverse events (AEs) and upper gastrointestinal (UGI) tolerability. A patient was determined to have had a UGI event if they reported at least one of the following: moderate or severe nausea, moderate or severe abdominal pain, or moderate or severe dyspepsia.

Data on patient demographics, change in VAS and WOMAC, and safety were compared for each trial. All Asian patients in the non-Asian trial (10.4% of all patients, 8.4% of whom were treated with celecoxib or placebo) were excluded from the analysis. For patient demographics, *P* values were determined by *t* test or by Chi-square test. For efficacy assessments, least squares (LS) means and *P* values are from the treatment--study interaction, based on an analysis of variance model, with change from baseline as the dependent variable; study, baseline, and treatment as the significant demographics in the comparison; and treatment--study interaction as the covariates. The primary efficacy analysis was conducted on the efficacy-evaluable population, which included patients who were randomized, received at least one dose of study medication, and who had no major protocol violations; both baseline and Week 6 assessments of the primary efficacy variable; adequate treatment (i.e., compliance rate of 70--120% during the 6-week study period); and had taken study medication within 48 h prior to week 6 visit (because the minimum washout period of ibuprofen was 2 days). Safety outcomes are reported for Asian and non-Asian patients who were randomized and received at least one dose of study medication.

Results {#Sec4}
=======

This analysis included a total of 441 patients randomized to celecoxib or placebo; of these, 329 efficacy-evaluable patients were included in the primary efficacy analysis. The Asian population was significantly older and smaller in body size, and had a shorter duration of OA than those in the non-Asian population (*P* \< 0.005 for each, Table [1](#Tab1){ref-type="table"}). In the Asian population, 121 patients were treated with celecoxib and 58 treated with placebo. In the non-Asian population, 108 patients were treated with celecoxib and 42 with placebo. A comparison of the change in pain score with celecoxib and placebo in each trial indicated no significant difference between Asian and non-Asian patients (Table [2](#Tab2){ref-type="table"}).Table 1Patient demographics in Asian and non-Asian trial populationsAsian^a^Non-Asian^b^*P* valueCelecoxibPlaceboCelecoxibPlacebo*n*1457815266Gender, *n* (%)0.1177^c^ Female97 (67)52 (67)88 (58)42 (64) Male48 (33)26 (33)64 (42)24 (36)Age, mean (SD), years65.9 (11.1)63.9 (11.1)58.4 (10.9)55.6 (10.4)\<0.0001^d^Race, *n* (%)\<0.0001^c^ Asian145 (100)78 (100)00 White0093 (61)39 (59) Black0037 (24)16 (24) Other0022 (14)11 (17)Weight, mean (SD), kg66.5 (13.3)65.6 (12.4)87.9 (19.3)89.0 (22.2)\<0.0001^d^Height, mean (SD), cm158.6 (8.0)158.2 (7.5)168.9 (9.7)165.8 (10.7)\<0.0001^d^BMI, mean (SD), kg/m^2^26.4 (4.8)26.1 (4.2)30.7 (5.8)32.4 (7.5)\<0.0001^d^Duration of OA, years Mean (SD)4.5 (4.0)4.6 (4.3)6.5 (7.4)6.2 (8.1)0.0021^d^ Median3.03.23.14.0*BMI* body mass index, *OA* osteoarthritis, *SD* standard deviation^a^ Patients from study A3191052^b^ Patients from study A3191063, excluding Asian patients^c^ Assessed by Chi-square test^d^ Assessed by *t* test Table 2Change in pain score (VAS) at endpoint in Asian and non-Asian trial populationsAsian^a^Non-Asian^b^CelecoxibPlaceboCelecoxibPlacebo*n*1215810842Baseline, mean (SE)65.1 (1.1)63.7 (1.5)68.4 (1.1)66.2 (2.0)Week 6, mean (SE)21.7 (1.9)25.6 (3.1)28.5 (2.2)34.9 (3.8)Change from baseline, LS mean (SE)−41.4 (2.3)−38.6 (3.2)−40.3 (2.3)−33.4 (3.5)Difference in LS mean vs. non-Asian^c^ LS mean−1.1−5.2---- 95% confidence interval−7.7, 5.5−14.8, 4.4---- *P* value0.74000.2870----*LS* least squares, *SE* standard error, *VAS* visual analog scale^a^Patients from study A3191052^b^Patients from study A3191063, excluding Asian patients^c^LS mean and *P* value are for treatment--study interaction, based on a general linear model with change from baseline as the dependent variable; with study, baseline, and treatment as the significant demographics in the comparison; and treatment--study interaction as the covariant

In the Asian population, mean (standard error \[SE\]) WOMAC Total Domain Scores at baseline were 50.5 (1.3) and 50.2 (1.9), with an LS mean (SE) change at endpoint of −29.0 (1.8) and −23.7 (2.4), for celecoxib and placebo, respectively. In the non-Asian population, mean (SE) WOMAC scores were 52.6 (1.0) and 57.6 (1.8) at baseline, and the change at endpoint (SE) was −24.7 (1.6) and −19.6 (2.5), for celecoxib and placebo, respectively. There was no significant difference between the two populations in the change at week 6 with celecoxib (*P* = 0.0842) or placebo (*P* = 0.2475).

Treatment-emergent all-causality AEs were broadly similar in the Asian and non-Asian populations (Table [3](#Tab3){ref-type="table"}). The percentage of patients with AEs with celecoxib were comparable in each population, wherein the most common AEs were abdominal pain, depression, and headache. The percentage of all patients with AEs was lower in those treated with celecoxib than with the active comparator: (27.6% of patients with celecoxib versus 46.1% with naproxen in the Asian trial; 31.9% with celecoxib versus 38.3% with ibuprofen in the non-Asian trial). There were fewer UGI events with celecoxib than with the active comparator in both full trial populations (3.4% of patients with celecoxib versus 6.4% with naproxen in the Asian trial; 1.9% with celecoxib versus 5.8% with ibuprofen in the non-Asian trial.Table 3Adverse events (all-causality) in Asian and non-Asian trial populationsAsian^a^Non-Asian^b^CelecoxibPlaceboCelecoxibPlacebo*n*1457614765Number of AEs64338144 Patients with AEs, *n* (%)40 (27.6)22 (28.9)49 (33.3)26 (40.0) Patients with serious AEs, *n* (%)001 (0.7)0 Patients discontinued due to AEs, *n* (%)10 (6.9)3 (3.9)5 (3.4)5 (7.7)GI-related AEs, *n* (%) Abdominal pain11 (7.6)3 (3.9)4 (2.7)3 (4.6) Dyspepsia2 (1.4)04 (2.7)1 (1.5) Constipation001 (0.7)1 (1.5) Diarrhea2 (1.4)01 (0.7)0 Nausea1 (0.7)1 (1.3)6 (4.1)0CNS-related AEs, *n* (%) Depression11 (7.6)11 (14.5)12 (8.2)9 (13.8) Dizziness01 (1.3)01 (1.5) Headache3 (2.1)06 (4.1)3 (4.6)*AE* adverse event, *CNS* central nervous system, *GI* gastrointestinal^a^Study A3191052 conducted in Asian patients^b^Study A3191063, excluding Asian patients

Discussion {#Sec5}
==========

In this comparison of the efficacy and safety of celecoxib for the treatment of OA of the knee, there was no significant difference between a population of Asian patients and a mixed population of non-Asian patients. This comparison benefits from utilizing patient-level data from two trials of notably similar design. Both trials were conducted in the United States over a similar time period, employed the same inclusion and exclusion criteria, and assessed the same efficacy endpoints.

It is notable that despite significant clinical and demographic differences between the Asian and non-Asian populations in this analysis, with Asian patients being significantly shorter, having lower body weight, being older, and having a shorter duration of disease than non-Asian patients (which may have led to differences in treatment pharmacokinetics and pharmacodynamics), efficacy and safety outcomes in each trial were similar. The finding that, in addition to pain assessments, there was also no significant difference in the improvement in patient function, as assessed by WOMAC score, supports this conclusion. There appeared to be a trend toward a greater change in pain score with placebo in the Asian population; however, this was not significantly different from the placebo response in the non-Asian population.

Although safety outcomes in each population were similar, discontinuations due to AEs were numerically greater in the Asian population, as was the incidence of abdominal pain. The total proportion of patients who discontinued was similar for patients in the Asian and non-Asian trials with celecoxib (18.6% vs. 18.2%, respectively) and placebo (24.4% vs. 26.0%, respectively). The reasons for discontinuation were also similar in each trial, with protocol violation and patient default being the most common causes. These studies were not designed, or powered, to evaluate cardiovascular safety; however, all NSAIDs have been associated with an increased risk of myocardial infarction with no notable difference between celecoxib and traditional NSAIDs \[[@CR11], [@CR12]\].

Limitations {#Sec6}
===========

Responses to some treatments have been suggested to vary across ethnic groups, potentially based on a degree of "ethnic sensitivity" in the pharmacokinetics and pharmacodynamics of some treatments \[[@CR13]\]. While not the focus of the design of these studies or a specific aim of this analysis, there have been shown to be differences in the perception of pain in individual patients with rheumatic disease, with factors such as depression and catastrophizing being associated with reported severity of pain, sensitivity to pain, disability, and poor treatment outcomes \[[@CR14]\]. Some studies have demonstrated differences between ethnic groups in the perception of pain intensity \[[@CR15]--[@CR19]\]. However, others have suggested that, when confounding variables are accounted for, any ethnic differences in perception of pain intensity are minimal \[[@CR20]\]. The latter conclusion is consistent with the findings of this analysis, wherein Asian patients with OA did not differ from non-Asian patients in their response to celecoxib. However, this conclusion is limited by the fact that these studies were not designed to assess ethnic differences in perception of pain intensity and, as such, do not provide any specific new information to address this question. At the same time, it should be noted that the Asian population in this analysis would likely consist of multiple ethnic groups from throughout Asia. Although the patients in this analysis were not genetically tested, there could be significant differences between Asian patients and non-Asian patients in the activity of cytochrome P450 2C9 (CYP2C9), the principal metabolizer of celecoxib \[[@CR21]\], which could confound the interpretation of these data.

That the Asian population in this comparison was based in the United States could also be perceived as a limitation, as there will be cultural differences between this population and patients living in Asia. It has been suggested that differences in pain perception in Asian populations may actually be driven by acculturation, with patients who are in the process of adapting, culturally and physiologically, to a new culture experiencing heightened pain responses, although this only affects the first-generation of relocated individuals \[[@CR22]\]. If this is the case, then this comparison, with an Asian population based in the United States, may be more likely to detect differences in the response to celecoxib.

Conclusions {#Sec7}
===========

This analysis did not detect any significant difference between Asian and non-Asian patients in the response to celecoxib for treatment of OA of the knee despite differences in size, age, and duration of disease. This information will likely be useful for physicians assessing treatment options for Asian patients with OA. Due to the smaller size of some Asian patients with OA, physicians may be tempted to decrease the dose of celecoxib below the therapeutic range recognized by regulatory authorities; these data suggest that dose changes are not necessary.
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